Expression data for human chronic myeloid leukemia K562 cell line (KS) and adriamycin induced multidrug-resistant K562/ADR (KA) cell line before and after treatment with hypomethylating agent decitabine

To explore the mechanisim and signaling pathway of hypomethylating agent decitabine in reversing P-glycoprotein(P-gp) induced multidrug resistance, we used adriamycin to treat drug sensitive human chronic myeloid leukemia K562 cells(KS) and successfully induced multidrug-resistant K562/ADR (KA) cells that higher expression of drug efflux pump P-gp. Gene expression profile was used to analysis the difference gene expression before and after treated with decitabine in both KS and KA cells. human chronic myeloid leukemia K562 cells (KS) and adriamycin induced multidrug-resistant K562/ADR (KA) cells were separately treated with hypomethylating agent decitabine, and then cells were selected for RNA extraction and hybridization on Affymetrix microarrays. We sought to obtain the difference expression gene in order to explore the signaling pathway and mechanism of decitabine in revering the multidrug resistance induced by drug efflux pump P-glycoprotein(P-gp).